Exceeded 10,000 patients treated to date with CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) Increased CARVYKTI ® manufacturing capacity with the physical expansion of the Raritan facility, now the ...
SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial results and key ...
Promising first-in-human results from allogeneic CAR-T candidate LUCAR-G39D demonstrate encouraging safety and efficacy in B-cell non-Hodgkin lymphoma SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- ...
Everybody from fans to media pundits alike have their opinions on the Arizona Cardinals amid a 2025 season that carries expectations of a postseason push, though rarely do we hear from former NFL ...
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 million EC and U.S. FDA label updates for CARVYKTI ® to include overall survival benefit versus standard of care ...
We use Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share (which we sometimes refer to as “Adjusted EPS” or “ANI per Share”, respectively) as performance metrics. Adjusted Net Income ...
We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as “Adjusted EPS” “ANL per Share”) as performance metrics. Adjusted Net Loss and ANL per share are not defined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results